Mercy Corps

Mercy BioAnalytics is a biotechnology company focused on the early detection of cancer through its proprietary Mercy Halo platform. The company's technology leverages the analysis of extracellular vesicles (EVs), which are shed in high abundance by tumor cells even at the earliest stages of disease. By identifying specific combinations of co-localized biomarkers on individual EVs, Mercy BioAnalytics aims to develop highly sensitive, specific, and low-cost blood-based tests. The company is initially prioritizing the development of screening tools for ovarian and lung cancers, where early detection is critical for improving patient survival rates. Mercy BioAnalytics is headquartered in Waltham, Massachusetts, and has secured significant venture funding to advance its clinical validation and commercialization efforts.